Research & Literature

Granulomatous Vasculitis.

Sharma A, Dogra S, Sharma K

Dermatologic clinics 2015; (33(3)):475-87.

Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA-Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis Referral Center.

Schirmer JH, Wright MN, Herrmann K, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2016; (68(12)):2953-2963 doi:10.1002/art.39786.

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.

Yates M, Watts RA, Bajema IM, et al.

Annals of the rheumatic diseases 2016; (75(9)):1583-94 doi:10.1136/annrheumdis-2016-209133.

Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Pepper RJ, Draibe JB, Caplin B, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2017; (69(1)):185-193 doi:10.1002/art.39814.

The clinical presentation and therapy of diseases related to anti-neutrophil cytoplasmic antibodies (ANCA).

Weiner M, Segelmark M

Autoimmunity reviews 2016; (15(10)):978-82.

Overview of the Pathogenesis of ANCA-Associated Vasculitis.

Xiao H, Hu P, Falk RJ, Jennette JC

Kidney diseases (Basel, Switzerland) 2016; (1(4)):205-15 doi:10.1159/000442323.

Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis.

van Daalen EE, Rizzo R, Kronbichler A, et al.

Annals of the rheumatic diseases 2017; (76(6)):1064-1069 doi:10.1136/annrheumdis-2016-209925.

A Rare Case of Digital Ischemia and Gangrene in ANCA-Associated Vasculitis with Review of the Literature.

Lau RA, Bains R, Suraweera D, et al.

Case reports in rheumatology 2017; (2017()):2421760 doi:10.1155/2017/2421760.

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

Wechsler ME, Akuthota P, Jayne D, et al.

The New England journal of medicine 2017; (376(20)):1921-1932 doi:10.1056/NEJMoa1702079.

C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis.

Dick J, Gan PY, Ford SL, et al.

Kidney international 2018; (93(3)):615-625 doi:10.1016/j.kint.2017.09.018.

Risk Factors for Relapse of Antineutrophil Cytoplasmic Antibody-associated Vasculitis in Japan: A Nationwide, Prospective Cohort Study.

Hara A, Wada T, Sada KE, et al.

The Journal of rheumatology 2018; (45(4)):521-528 doi:10.3899/jrheum.170508.

Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.

Terrier B, Pagnoux C, Perrodeau É, et al.

Annals of the rheumatic diseases 2018; (77(8)):1150-1156 doi:10.1136/annrheumdis-2017-212768.

Update on the epidemiology, risk factors, and outcomes of systemic vasculitides.

Berti A, Dejaco C

Best practice & research. Clinical rheumatology 2018; (32(2)):271-294 doi:10.1016/j.berh.2018.09.001.

Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome.

Wester Trejo MAC, Floßmann O, Westman KW, et al.

Rheumatology (Oxford, England) 2019; (58(1)):103-109 doi:10.1093/rheumatology/key260.

Central Nervous System Involvement in ANCA-Associated Vasculitis: What Neurologists Need to Know.

Zheng Y, Zhang Y, Cai M, et al.

Frontiers in neurology 2018; (9()):1166 doi:10.3389/fneur.2018.01166.

Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.

McClure ME, Wason J, Gopaluni S, et al.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2019; (25(5)):217-223 doi:10.1097/RHU.0000000000001030.

Clinical associations of renal involvement in ANCA-associated vasculitis.

Kronbichler A, Shin JI, Lee KH, et al.

Autoimmunity reviews 2020; (19(4)):102495 doi:10.1016/j.autrev.2020.102495.

Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA.

Nishi R, Koike H, Ohyama K, et al.

Neurology 2020; (94(16)):e1726-e1737 doi:10.1212/WNL.0000000000009309.

B-cell treatment in ANCA-associated vasculitis.

Karras A, Lazareth H, Chauvet S

Rheumatology (Oxford, England) 2020; (59(Suppl 3)):iii68-iii73 doi:10.1093/rheumatology/kez605.

The role of plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis.

Bellos I, Michelakis I, Nikolopoulos D

Clinical rheumatology 2021; (40(4)):1447-1456 doi:10.1007/s10067-020-05390-z.

Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss).

Papo M, Sinico RA, Teixeira V, et al.

Rheumatology (Oxford, England) 2021; (60(9)):4355-4360 doi:10.1093/rheumatology/keaa805.

Avacopan for the Treatment of ANCA-Associated Vasculitis.

Jayne DRW, Merkel PA, Schall TJ, et al.

The New England journal of medicine 2021; (384(7)):599-609 doi:10.1056/NEJMoa2023386.

Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody（ANCA）-associated vasculitis.

Tsukui D, Kimura Y, Kono H

Journal of translational autoimmunity 2021; (4()):100094 doi:10.1016/j.jtauto.2021.100094.

Uncommon Presentation of Granulomatosis with Polyangiitis Mimicking Metastatic Lung Cancer.

Urbanska EM, Elversang J, Colville-Ebeling B, et al.

Clinics and practice 2021; (11(2)):293-302 doi:10.3390/clinpract11020042.

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Chung SA, Langford CA, Maz M, et al.

Arthritis care & research 2021; (73(8)):1088-1105 doi:10.1002/acr.24634.

Oral cyclophosphamide-induced posterior reversible encephalopathy syndrome in a patient with ANCA-associated vasculitis: A case report.

Kim Y, Kwak J, Jung S, et al.

World journal of clinical cases 2021; (9(21)):6130-6137 doi:10.12998/wjcc.v9.i21.6130.

ANCA-Associated Vasculitic Neuropathies: A Review.

Koike H, Nishi R, Ohyama K, et al.

Neurology and therapy 2022; (11(1)):21-38 doi:10.1007/s40120-021-00315-7.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis.

Robson JC, Grayson PC, Ponte C, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2022; (74(3)):393-399 doi:10.1002/art.41986.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis.

Grayson PC, Ponte C, Suppiah R, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2022; (74(3)):386-392 doi:10.1002/art.41982.

[ANCA-associated small-vessel vasculitides].

Bayrashevskaya AV, Degtyareva ND, Radenska-Lopovok SG

Arkhiv patologii 2022; (84(1)):50-58 doi:10.17116/patol20228401150.

Clinical Characteristics and Outcomes of Patients With ANCA-Associated Vasculitides in a Colombian Hospital.

Santacruz-Sandoval E, López-Bonilla J, Guevara-Calderón LA, et al.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2022; (28(2)):e491-e497 doi:10.1097/RHU.0000000000001775.

Pentraxin-3 - a potential biomarker in ANCA-associated vasculitis.

Jonasdottir AD, Antovic A, Qureshi AR, et al.

Scandinavian journal of rheumatology 2023; (52(3)):293-301 doi:10.1080/03009742.2022.2045790.

Performance of MPO-ANCA and PR3-ANCA immunoassays for the stratification of specific ANCA-associated vasculitis: A systematic review and meta-analysis.

Walker BS, Peterson LK, Koening C, et al.

Autoimmunity reviews 2022; (21(6)):103100 doi:10.1016/j.autrev.2022.103100.

Diagnostic and Therapeutic Approach in ANCA-Associated Glomerulonephritis: A Review on Management Strategies.

Molnár A, Studinger P, Ledó N

Frontiers in medicine 2022; (9()):884188 doi:10.3389/fmed.2022.884188.

The Complement System and ANCA Associated Vasculitis in the Era of Anti-Complement Drugs.

Kimoto Y, Horiuchi T

Frontiers in immunology 2022; (13()):926044 doi:10.3389/fimmu.2022.926044.

The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target.

Mazzariol M, Manenti L, Vaglio A

Current opinion in rheumatology 2023; (35(1)):31-36 doi:10.1097/BOR.0000000000000914.

Ocular manifestations of ANCA-associated vasculitis.

Junek ML, Zhao L, Garner S, et al.

Rheumatology (Oxford, England) 2023; (62(7)):2517-2524 doi:10.1093/rheumatology/keac663.

Granulomatosis With Polyangiitis: A Clinical Case.

Rodrigues F, Oliveira Sá AI, Mendes M, et al.

Cureus 2022; (14(12)):e32410 doi:10.7759/cureus.32410.

Development and Validation of a Simulation Model for Treatment to Maintain Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Wallace ZS, Stone JH, Fu X, et al.

Arthritis care & research 2023; (75(9)):1976-1985 doi:10.1002/acr.25088.

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.

Smith RM, Jones RB, Specks U, et al.

Annals of the rheumatic diseases 2023; (82(7)):937-944 doi:10.1136/ard-2022-223559.

[Granulomatosis with polyangiitis: what's new?]

Ringwald M, Chevalley D, Bongard C, et al.

Revue medicale suisse 2023; (19(821)):674-679 doi:10.53738/REVMED.2023.19.821.674.

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV.

Sanchez-Alamo B, Schirmer JH, Hellmich B, et al.

RMD open 2023; (9(2)) doi:10.1136/rmdopen-2023-003083.

Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial.

Geetha D, Dua A, Yue H, et al.

Annals of the rheumatic diseases 2024; (83(2)):223-232 doi:10.1136/ard-2023-224816.

The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.

Strand V, Jayne DRW, Horomanski A, et al.

The Lancet. Rheumatology 2023; (5(8)):e451-e460 doi:10.1016/S2665-9913(23)00092-9.

Diagnosis and management of ANCA-associated vasculitis.

Kronbichler A, Bajema IM, Bruchfeld A, et al.

Lancet (London, England) 2024; (403(10427)):683-698 doi:10.1016/S0140-6736(23)01736-1.

Proteinase 3-specific antineutrophil cytoplasmic antibody-associated vasculitis.

Falde SD, Fussner LA, Tazelaar HD, et al.

The Lancet. Rheumatology 2024; (6(5)):e314-e327 doi:10.1016/S2665-9913(24)00035-3.

Pathogenesis of Pulmonary Manifestations in ANCA-Associated Vasculitis and Goodpasture Syndrome.

Fouka E, Drakopanagiotakis F, Steiropoulos P

International journal of molecular sciences 2024; (25(10)) doi:10.3390/ijms25105278.

Granulomatosis with polyangiitis mimicking multisystem pyoderma gangrenosum: A case report.

Gormley A, Green P

SAGE open medical case reports 2024; (12()):2050313X241304229 doi:10.1177/2050313X241304229.

How We Treat ANCA-Associated Vasculitis: A Focus on the Maintenance Therapy.

Roccatello D, Fenoglio R, De Simone E, Sciascia S

Journal of clinical medicine 2025; (14(1)) doi:10.3390/jcm14010208.

Practical Management of ANCA-Associated Vasculitis: A Clinician's Perspective.

Stacey HL, Francis L, Smith RM, Jones RB

Glomerular diseases 2025; (5(1)):84-102 doi:10.1159/000543159.

Highlights from the breakout session: optimising new treatments.

Francis L, Dhutia A, Pusey C, Jones RB

Rheumatology (Oxford, England) 2025; (64(Supplement_1)):i117-i119 doi:10.1093/rheumatology/keae426.

A Rare Coexistence of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis and IgG4-Related Disease: A Case Report and Literature Review.

Al-Saedi ZS, Alatta L, Miqdad MA, et al.

Cureus 2025; (17(8)):e89738 doi:10.7759/cureus.89738.

Diabetes mellitus and cardiac disease as key predictors of rituximab-induced acute thrombocytopenia in ANCA-associated vasculitis.

Akao S, Shimizu M, Maruo K, et al.

Rheumatology (Oxford, England) 2026; (65(1)) doi:10.1093/rheumatology/keaf529.

Factors associated with pauci-immune glomerulonephritis in patients undergoing kidney biopsy with positive anti-neutrophil cytoplasmic antibody results.

Lee YJ, Lee J, Ahn SM, et al.

Journal of nephrology 2025; (38(9)):2919-2928 doi:10.1007/s40620-025-02430-2.

Recent pathogenetic insights and therapeutic advances in ANCA-associated vasculitis.

Sagy I, Jayne DRW

Annals of the rheumatic diseases 2025; doi:10.1016/j.ard.2025.11.024.

Comparison of Rituximab and Cyclophosphamide for Induction Therapy in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: A Systematic Review of Randomized Trials and Comparative Cohort Evidence.

Khan SH, Manzoor MZ, Khan J

Cureus 2025; (17(12)):e99868 doi:10.7759/cureus.99868.

First presentation of idiopathic granulomatosis with polyangiitis in an adolescent.

Ashworth G, Sanmani S

BMJ case reports 2026; (19(2)) doi:10.1136/bcr-2025-266449.